WO2006075523A1 - 血中コレステロール低下用経口組成物 - Google Patents
血中コレステロール低下用経口組成物 Download PDFInfo
- Publication number
- WO2006075523A1 WO2006075523A1 PCT/JP2005/023880 JP2005023880W WO2006075523A1 WO 2006075523 A1 WO2006075523 A1 WO 2006075523A1 JP 2005023880 W JP2005023880 W JP 2005023880W WO 2006075523 A1 WO2006075523 A1 WO 2006075523A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isoflavone
- cholesterol
- oral composition
- blood cholesterol
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a composition for lowering blood cholesterol.
- Patent Document 1 JP-A-9-255570. Also reported is a method to reduce the risk of atherosclerosis by reducing LDL-cholesterol and increasing HDL cholesterol using one of the isoflavones daidzein! (Patent Document 2: Japanese Patent Laid-Open No. 11 13 9973).
- Patent Document 2 Japanese Patent Laid-Open No. 11 13 9973.
- DFA Difructose antideridide
- Patent Document 3 Japanese Patent Publication No. 3-5788
- Patent Document 4 Patent No. 3514955
- Patent Document 5 Japanese Patent Laid-Open No. 2003-321311
- Patent Document 1 JP-A-9 255570
- Patent Document 2 Japanese Patent Laid-Open No. 11-139973
- Patent Document 3 Japanese Patent Publication No. 3-5788
- Patent Document 4 Japanese Patent No. 3514955
- Patent Document 5 Japanese Unexamined Patent Application Publication No. 2003-321371
- Patent Document 6 Japanese Unexamined Patent Publication No. 2000-154143
- composition exhibiting a blood cholesterol lowering effect.
- the main constitution of the present invention is that blood cholesterol is characterized by enhancing the cholesterol-lowering action of isoflavone by containing difructose antideridide, isoflavone and Z or a derivative thereof as active ingredients.
- Oral composition for lowering blood cholesterol is characterized by enhancing the cholesterol-lowering action of isoflavone by containing difructose antideridide, isoflavone and Z or a derivative thereof as active ingredients.
- Oral composition for lowering blood cholesterol is characterized by enhancing the cholesterol-lowering action of isoflavone by containing difructose antideridide, isoflavone and Z or a derivative thereof as active ingredients.
- An oral composition for lowering blood cholesterol comprising difructose anhydride, isoflavone and Z or a derivative thereof as active ingredients.
- An oral composition for lowering blood cholesterol comprising difructose anhydride, daidzein and Z or a derivative thereof as active ingredients.
- An oral composition for lowering blood cholesterol characterized by enhancing the cholesterol-lowering action of isoflavone by containing difructose anhydride, isoflavone and Z or a derivative thereof as active ingredients.
- An oral composition for lowering cholesterol in blood which comprises enhancing the cholesterol lowering action of daidzein by containing difructose anhydride, daidzein, and Z or a derivative thereof as active ingredients.
- a pet animal medicine or pet animal feed comprising the composition according to any one of (1) to (4).
- a composition containing DFA, isoflavone and Z or a derivative thereof of the present invention exhibits a blood cholesterol lowering action.
- the DFA referred to in the present invention is a known substance, which is an anhydrocyclic disaccharide bonded to two fructose at two points.
- inulin is produced by an inulin-degrading enzyme, such as inulin flatrate transferase (EC2.4.1.93) produced by Arthrobacter sp. It can be produced by fermenting or fermenting levuanfructotransferase (EC2.4.1.10) produced by Arthrobacternicotinovorans GS-9.
- DFA derivatives due to differences in the binding mode of the two molecules of fructose
- DFAI DFAII
- DFAIII DFAIV
- DFAV DFAV
- DFAIII and DFAIV which are excellent in industrial production efficiency, purified and excellent in stability of power, are preferably used.
- the oral composition according to the present invention contains DFA as an active ingredient, and can be used as a composition of a pharmaceutical product type or a food / drink product (including a pet animal feed) type composition.
- a pharmaceutical product type or a food / drink product (including a pet animal feed) type composition for example, there are no limitations as long as it is a form that can be finally administered orally, such as pharmaceuticals for humans or pet animals, foods and drinks, formula milk powder, enteral nutrition, health foods and drinks, and food additives.
- Most preferably used in the present invention is a form in which DFA, isoflavone and Z or a derivative thereof are delivered to the large intestine without being absorbed, for example, a form in which enteric capsules are contained.
- the content of the active ingredient is not particularly limited.
- DFA When used as a food-and-drink type composition, DFA can be used as it is or in combination with other foods or food ingredients, and can be used according to conventional methods. In addition, since the heat stability and the acid stability are both high in processing, ordinary food processing methods can be applied without any problems.
- Food-type oral compositions containing DFA are powdered, granular, paced There is no particular limitation such as a toroid, liquid, suspension, tablet or capsule. For example, the preparation of healthy drinks using various ingredients commonly used in the manufacture of sweeteners, acidulants, vitamins and other drinks can also be exemplified.
- the active ingredient When used as a pharmaceutical type composition, the active ingredient is administered in various forms.
- the dosage form include oral administration using tablets, capsules, granules, powders, syrups and the like. These various preparations are usually used in the pharmaceutical formulation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizing agents, suspension agents, coating agents, etc. Can be formulated using known adjuvants.
- the dosage varies depending on symptoms, age, body weight, and dosage form. Normally, it is administered to adults in the range of 0.5 to 2000 mg per kg body weight, preferably 1 to 1000 mg per day when administered orally. It is good.
- the isoflavone of the present invention refers to a component having an isoflavone skeleton, which is generally named as genistein, daidzein, glycitin, etc., and its derivative refers to a glycoside and Z or acetylated or malonic Derivatives that have been modified such as Louis candy.
- daidzein and Z or derivatives thereof which are converted to etaol having a stronger activity by intestinal bacteria are preferably used.
- the isoflavones and Z or derivatives thereof used in the present invention can be derived from chemically synthesized products, natural product extracts and processed products thereof, and plants.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05822703A EP1839663A4 (en) | 2005-01-12 | 2005-12-27 | ORAL COMPOSITION REDUCING THE CHOLESTEROL RATE IN BLOOD |
US11/813,731 US20080132466A1 (en) | 2005-01-12 | 2005-12-27 | Blood Cholesterol Reducing Oral Composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005005738A JP2006193459A (ja) | 2005-01-12 | 2005-01-12 | 血中コレステロール低下用経口組成物 |
JP2005-005738 | 2005-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006075523A1 true WO2006075523A1 (ja) | 2006-07-20 |
Family
ID=36677551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/023880 WO2006075523A1 (ja) | 2005-01-12 | 2005-12-27 | 血中コレステロール低下用経口組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080132466A1 (ja) |
EP (1) | EP1839663A4 (ja) |
JP (1) | JP2006193459A (ja) |
CN (1) | CN101094678A (ja) |
WO (1) | WO2006075523A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH035788B2 (ja) * | 1987-04-28 | 1991-01-28 | Norinsuisansho Shokuhin Sogo Kenkyushocho | |
JPH05168419A (ja) * | 1991-06-05 | 1993-07-02 | Mitsubishi Kasei Corp | 動物の脂肪低減剤及びこれを用いる動物の飼育方法 |
JPH09255570A (ja) * | 1996-03-21 | 1997-09-30 | Fujitsuko Kk | 血中脂質濃度を低減させる薬剤及び可食性組成物 |
JPH11139973A (ja) * | 1997-09-19 | 1999-05-25 | Protein Technol Internatl Inc | 血中のldl−コレステロール濃度を減少しhdl−コレステロール濃度を増加させ、アテローム硬化症及び道管病の危険性を減少させる方法 |
JP2004161619A (ja) * | 2002-11-11 | 2004-06-10 | Fancl Corp | 骨形成促進組成物 |
JP2005225838A (ja) * | 2004-02-16 | 2005-08-25 | Fancl Corp | ダイフラクトースアンハイドライド含有経口組成物 |
JP2006022003A (ja) * | 2004-07-06 | 2006-01-26 | Fancl Corp | Dfa含有難吸収水溶性生理活性物質吸収促進剤。 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0656786T3 (da) * | 1992-05-19 | 2004-11-08 | Novogen Res Pty Ltd | Anvendelse af isoflavonphytoöstrogenekstrakter af soja eller klöver |
US7285297B1 (en) * | 1999-04-23 | 2007-10-23 | Archer-Daniels-Midland Company | Method of reducing low density liproprotein cholesterol concentration |
WO2003090759A1 (fr) * | 2002-04-26 | 2003-11-06 | Fancl Corporation | Composition contenant du difructose anhydride et utilisation de celle-ci |
JP4723849B2 (ja) * | 2004-11-17 | 2011-07-13 | 株式会社ファンケル | ダイフラクトースアンハイドライド含有経口組成物 |
-
2005
- 2005-01-12 JP JP2005005738A patent/JP2006193459A/ja active Pending
- 2005-12-27 US US11/813,731 patent/US20080132466A1/en not_active Abandoned
- 2005-12-27 EP EP05822703A patent/EP1839663A4/en not_active Withdrawn
- 2005-12-27 WO PCT/JP2005/023880 patent/WO2006075523A1/ja active Application Filing
- 2005-12-27 CN CNA2005800458004A patent/CN101094678A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH035788B2 (ja) * | 1987-04-28 | 1991-01-28 | Norinsuisansho Shokuhin Sogo Kenkyushocho | |
JPH05168419A (ja) * | 1991-06-05 | 1993-07-02 | Mitsubishi Kasei Corp | 動物の脂肪低減剤及びこれを用いる動物の飼育方法 |
JPH09255570A (ja) * | 1996-03-21 | 1997-09-30 | Fujitsuko Kk | 血中脂質濃度を低減させる薬剤及び可食性組成物 |
JPH11139973A (ja) * | 1997-09-19 | 1999-05-25 | Protein Technol Internatl Inc | 血中のldl−コレステロール濃度を減少しhdl−コレステロール濃度を増加させ、アテローム硬化症及び道管病の危険性を減少させる方法 |
JP2004161619A (ja) * | 2002-11-11 | 2004-06-10 | Fancl Corp | 骨形成促進組成物 |
JP2005225838A (ja) * | 2004-02-16 | 2005-08-25 | Fancl Corp | ダイフラクトースアンハイドライド含有経口組成物 |
JP2006022003A (ja) * | 2004-07-06 | 2006-01-26 | Fancl Corp | Dfa含有難吸収水溶性生理活性物質吸収促進剤。 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1839663A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1839663A1 (en) | 2007-10-03 |
EP1839663A4 (en) | 2008-03-05 |
US20080132466A1 (en) | 2008-06-05 |
JP2006193459A (ja) | 2006-07-27 |
CN101094678A (zh) | 2007-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2342608A1 (en) | Bioflavonoid as blood glucose level lowering agent | |
WO2002055074A1 (fr) | Agents prophylactiques ou remedes contre l'arthrite | |
US20040105914A1 (en) | Health foods containing natto kinase and fermented milk products | |
CA2302641C (en) | Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation | |
WO2006054429A1 (ja) | ダイフラクトース アンハイドライド含有経口組成物 | |
JP2010111646A (ja) | 潰瘍性大腸炎治療剤 | |
JPH1084909A (ja) | 腸内酪酸濃度上昇促進剤 | |
JP2009107987A (ja) | 筋力向上剤 | |
JP2009120502A (ja) | キトサン含有組成物 | |
WO2002055073A1 (fr) | Agents prophylactiques de l'arthrite | |
WO2006075523A1 (ja) | 血中コレステロール低下用経口組成物 | |
JP4127863B2 (ja) | 腸内環境改善組成物 | |
WO2006038613A1 (ja) | ダイフラクトース アンハイドライド含有経口組成物 | |
EP0681788A2 (en) | Dioxabicyclo[3.3.0] octane derivatives, e.g. sesamin etc., for prevention or alleviation of allergy symptoms | |
JP3572103B2 (ja) | 二次胆汁酸低下剤 | |
JP2021136865A (ja) | 血糖値上昇抑制用機能食品、血糖値上昇抑制剤、及びα−グルコシダーゼ阻害剤 | |
CN101277617A (zh) | 治疗肌肉萎缩的含甜菜碱的营养品 | |
JP2005126429A (ja) | 免疫賦活剤、食品及び液状食品組成物 | |
JP2004161619A (ja) | 骨形成促進組成物 | |
JPS59132884A (ja) | ビフイズス菌増殖促進組成物 | |
WO2006085523A1 (ja) | 血糖値上昇抑制用組成物 | |
AU2006328982A1 (en) | Ethanol-preci pitated Phaseolus vulgaris extracts, their use and formulations | |
WO2020090789A1 (ja) | エクオールを有効成分として含む腸内細菌に対する抗菌剤 | |
JP2005247752A (ja) | 血中コレステロール上昇抑制剤 | |
CN115336758A (zh) | 低聚果糖在改善缺锌症状中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580045800.4 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005822703 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11813731 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005822703 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11813731 Country of ref document: US |